Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Embecta
EMBC
Embecta
Global Healthcare Margins Will Erode Under Tightening Reimbursement Pressures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
22 Jun 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$11.00
22.5% overvalued
intrinsic discount
16 Aug
US$13.48
Loading
1Y
-3.6%
7D
5.9%
Author's Valuation
US$11.0
22.5% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$11.0
22.5% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
1b
2019
2021
2023
2025
2027
2028
Revenue US$1.1b
Earnings US$185.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
0.09%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
11.77%
Calculation
US$185.67m
Earnings '28
x
4.96x
PE Ratio '28
=
US$920.12m
Market Cap '28
US$920.12m
Market Cap '28
/
60.90m
No. shares '28
=
US$15.11
Share Price '28
US$15.11
Share Price '28
Discounted to 2025 @ 11.71% p.a.
=
US$10.84
Fair Value '25
